Oculis Holding AG (OCS)
OCS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | OCS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | Not reported by the screener |
| SEC CIK | 0001953530 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-04 |
| Cash and burn | 81.3M CHF cash; operating cash flow -16.6M CHF a quarter. | Report 2025-12-31 |
| Shares outstanding | 57,984,438 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-11-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers AG, Lausanne, Switzerland | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -99.0M CHF | -66.3M CHF | 81.3M CHF | No debt tags | Needs four quarters | 20-F 2026-03-04 |
| FY 2024 2024-12-31 | Not filed | -85.8M CHF | -48.9M CHF | 27.7M CHF | No debt tags | Needs four quarters | 20-F 2026-03-04 |
| FY 2023 2023-12-31 | Not filed | -88.8M CHF | -55.0M CHF | 38.3M CHF | No debt tags | Needs four quarters | 20-F 2026-03-04 |
| FY 2022 2022-12-31 | Not filed | -38.7M CHF | -25.1M CHF | 19.8M CHF | No debt tags | Needs four quarters | 20-F 2025-03-11 |
| FY 2021 2021-12-31 | Not filed | -18.6M CHF | -13.8M CHF | 46.3M CHF | No debt tags | Needs four quarters | 20-F 2024-03-19 |
| FY 2020 2020-12-31 | Not filed | -14.9M CHF | -12.0M CHF | 5.0M CHF | No debt tags | Needs four quarters | 20-F 2023-03-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-03 |
| Latest annual report | 20-F | 2026-03-04 |
| Latest quarterly / interim | 6-K | 2026-11-03 |
Source: SEC EDGAR submissions feed, 138 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | +0.3% |
| 3 months | -40.4% |
| Year to date | -61.7% |
| 1 year | -60.4% |
| From 52-week high | -76.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| OCSAW | Oculis Holding AG Warrants | $1.90 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LYEL | Lyell Immunopharma Inc. | $14.65 | +2.45% | $469.0M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier